Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 10 2023 - 5:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 9, 2023
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Novo Nordisk A/S purchases B shares worth DKK 3,889 million from Novo Holdings A/S under the
2023 share repurchase programme
Bagsværd, Denmark, 9 May 2023 – Today, Novo Nordisk
A/S has entered into an agreement to purchase 3,506,250 B shares of DKK 0.20 at a value of DKK 3,889 million from Novo Holdings A/S. The
transaction is part of Novo Nordisk A/S’ 2023 share repurchase programme of up to a total of DKK 30 billion to be executed during
a 12-month period beginning 1 February 2023. The transaction price is DKK 1,109.23 per share and has been calculated as the three-day
volume weighted average market price from 4 May 2023 to 9 May 2023 in the open window following the announcement of Novo Nordisk A/S’
quarterly financial results.
Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.4%
of the share capital and 77.2% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 98,597,750
B shares of DKK 0.20, corresponding to 28.2% of the capital and 77.2% of the votes in Novo Nordisk A/S.
The transaction is in line with the announcement on 1 February 2023 that Novo Holdings A/S intends
to maintain its ownership of Novo Nordisk A/S’ share capital around 28%.
With the transactions stated above, Novo Nordisk A/S owns a total of 11,055,628 B shares of
DKK 0.20, corresponding to 0.5% of the share capital, as treasury shares. The total number of A and B shares in the company is 2,255,000,000
of DKK 0.20 including treasury shares.
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no: 24 25 67 90 |
|
|
Company announcement No 32 / 2023 |
Page 2 of 2
About Novo Holdings
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation.
The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive
long-term returns on the assets of the Novo Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder
of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio with a long-term return perspective. In addition to managing
a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences
investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all
stages of development.
As of year-end 2022, Novo Holdings had total assets of EUR 108 billion. www.novoholdings.dk
About Novo Nordisk A/S
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to
defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 57,100
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for further information
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com |
|
|
Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no: 24 25 67 90 |
|
|
Company announcement No 32 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 9, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024